ArticleInfection2026
Volume control but structural imbalance: AWaRe-based assessment of antimicrobial stewardship in Shanghai, China (2016-2024).
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRecognizing irrational use as the key driver of antimicrobial resistance (AMR), the World Health Organization (WHO) introduced the AWaRe (Access, Watch, Reserve) classification to enhance prescribing structures. This study aims to comprehensively elucidate the long-term trends and structural evolution of antimicrobial use, providing evidence to inform the transition from volume-based control to structure-oriented optimization.
methodsThe Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) method and AWaRe classification were applied to assess the overall antimicrobial use and structural rationality across institutions, and further analyzed concentration indices to reveal clinical dependence on a limited set of agents.
resultsFrom 2016 to 2024, the overall antimicrobial usage and expenditure decreased by 57.94% and 22.07% with strong concordance. However, the prescribing structure severely deviated from the WHO's target of ≥ 60.00% Access category. The proportion of Access category remained below 20.00%, while Watch category predominated but declined gradually, and Reserve category remained below 1.00% until a slight rebound after 2023, especially in secondary and tertiary hospitals. The annual top 10 agents consistently accounted for over 50.00%, exhibiting an initial decline in concentration followed by a slight rebound after 2021. In 2016, cefuroxime sodium injection constituted 63.50%, Herfindahl-Hirschman Index (HHI) was 0.41, later becoming more dispersed. Levofloxacin tablets have ranked first in utilization and remained high since 2022, contributing to a rebound in concentration (HHI = 0.06).
conclusionsAntimicrobial stewardship (AMS) in Shanghai, China has achieved success in controlling volume, but still faces structural challenges. Insufficient Access, prolonged dominance of broad-spectrum Watch, and Reserve slightly rebound suggest potential AMR escalation. It is recommended to implement tiered, structure-oriented strategies and integrate pathogen surveillance with clinical data to assess prescriptions and guide targeted AMR control.
Indexed as
Identifiers
42268496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.